Targeting GITR in cancer immunotherapy &#x2013; there is no perfect knowledge

Diwakar Davar; Roberta Zappasodi

doi:10.18632/oncotarget.28461

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

Diwakar Davar _ and Roberta Zappasodi

PDF | Full Text | How to cite | Press Release

Oncotarget. 2023; 14:614-621. https://doi.org/10.18632/oncotarget.28461

Metrics: PDF 707 views | Full Text 1440 views | ?

Abstract

Diwakar Davar1^,2 and Roberta Zappasodi3^,4

1 Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA

2 University of Pittsburgh, Pittsburgh, PA 15232, USA

3 Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, NY 10065, USA

4 Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, NY 10065, USA

Correspondence to:

Diwakar Davar,

email:

[email protected]

Keywords: cancer; immunotherapy; programmed death-1 (PD-1); cytotoxic T-lymphocyte Antigen-4 (CTLA-4); glucocorticoid-induced TNFR-related protein (GITR)

Received: April 19, 2023 Accepted: June 05, 2023 Published: June 19, 2023

Copyright: © 2023 Davar and Zappasodi. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Glucocorticoid-induced TNFR-related protein (GITR) belongs to the TNFR superfamily (TNFRSF) and stimulates both the acquired and innate immunity. GITR is broadly expressed on immune cells, particularly regulatory T cells (Tregs) and natural killer (NK) cells. Given its potential to promote T effector function and impede Treg immune suppression, GITR is an attractive target for cancer immunotherapy. Preclinically, GITR agonists have demonstrated potent anti-tumor efficacy singly and in combination with a variety of agents, including PD-1 blockade. Multiple GITR agonists have been advanced into the clinic, although the experience with these agents has been disappointing. Recent mechanistic insights into the roles of antibody structure, valency, and Fc functionality in mediating anti-tumor efficacy may explain some of the apparent inconsistency or discordance between preclinical data and observed clinical efficacy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28461

Publication Alerts

Research Perspectives:

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

Abstract